NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology. This nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial Antigen Presenting Cells (aAPC) that present antigens to T cells eliciting a highly targeted therapy driven by the patient’s immune system. These aAPC can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.
Our first product, for the treatment of cancer, is expected to enter clinical trials in 2018.
The AIM technology is the foundation for an innovative approach to immunotherapy in which immune system is guided by a synthetic aAPC that has been engineered to orchestrate a targeted T cell response.Learn More
Our first two products use aAPCs to stimulate multiple antigen-specific, cancer-fighting T cells for the treatment of cancer.